TY - JOUR T1 - Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial JF - medRxiv DO - 10.1101/2021.06.14.21258569 SP - 2021.06.14.21258569 AU - Meagan P. O’Brien AU - Eduardo Forleo-Neto AU - Neena Sarkar AU - Flonza Isa AU - Peijie Hou AU - Kuo-Chen Chan AU - Bret J. Musser AU - Katharine J. Bar AU - Ruanne V. Barnabas AU - Dan H. Barouch AU - Myron S. Cohen AU - Christopher B. Hurt AU - Dale R. Burwen AU - Mary A. Marovich AU - Elizabeth R. Brown AU - Ingeborg Heirman AU - John D. Davis AU - Kenneth C. Turner AU - Divya Ramesh AU - Adnan Mahmood AU - Andrea T. Hooper AU - Jennifer D. Hamilton AU - Yunji Kim AU - Lisa A. Purcell AU - Alina Baum AU - Christos A. Kyratsous AU - James Krainson AU - Richard Perez-Perez AU - Rizwana Mohseni AU - Bari Kowal AU - A. Thomas DiCioccio AU - Neil Stahl AU - Leah Lipsich AU - Ned Braunstein AU - Gary Herman AU - George D. Yancopoulos AU - David M. Weinreich AU - for the COVID-19 Phase 3 Prevention Trial Team Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/18/2021.06.14.21258569.abstract N2 - Importance Easy-to-administer antiviral treatments may be used to prevent progression from asymptomatic infection to COVID-19 and to reduce viral carriage.Objective Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS-CoV-2 infection to COVID-19.Design Randomized, double-blind, placebo-controlled, phase 3 study that enrolled asymptomatic close contacts living with a SARS-CoV-2–infected household member (index case). Participants who were SARS-CoV-2 RT-qPCR–positive at baseline were included in the analysis reported here.Setting Multicenter trial conducted at 112 sites in the United States, Romania, and Moldova.Participants Asymptomatic individuals ≥12 years of age were eligible if identified within 96 hours of collection of the index case’s positive SARS-CoV-2 test sample.Interventions A total of 314 asymptomatic, SARS-CoV-2 RT-qPCR–positive individuals living with an infected household contact were randomized 1:1 to receive a single dose of subcutaneous REGEN-COV 1200mg (n=158) or placebo (n=156).Main Outcome(s) and Measure(s) The primary endpoint was the proportion of participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. The key secondary efficacy endpoints were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (>4 log10 copies/mL). Safety was assessed in all treated participants.Results Subcutaneous REGEN-COV 1200mg significantly prevented progression from asymptomatic to symptomatic disease compared with placebo (31.5% relative risk reduction; 29/100 [29.0%] vs 44/104 [42.3%], respectively; P=.0380). REGEN-COV reduced the overall population burden of high–viral load weeks (39.7% reduction vs placebo; 48 vs 82 total weeks; P=.0010) and of symptomatic weeks (45.3% reduction vs placebo; 89.6 vs 170.3 total weeks; P=.0273), the latter corresponding to an approximately 5.6-day reduction in symptom duration per symptomatic participant. Six placebo-treated participants had a COVID-19–related hospitalization or ER visit versus none for those receiving REGEN-COV. The proportion of participants receiving placebo who had ≥1 treatment-emergent adverse events was 48.1% compared with 33.5% for those receiving REGEN-COV, including events related (39.7% vs 25.8%, respectively) or not related (16.0% vs 11.0%, respectively) to COVID-19.Conclusions and Relevance Subcutaneous REGEN-COV 1200mg prevented progression from asymptomatic SARS-CoV-2 infection to COVID-19, reduced the duration of high viral load and symptoms, and was well tolerated.Trial Registration ClinicalTrials.gov Identifier, NCT04452318Question Can treatment with the anti–SARS-CoV-2 antibody combination REGEN-COV prevent COVID-19 and reduce viral load when given to recently exposed and asymptomatic individuals?Findings In this randomized, double-blind, phase 3 trial, subcutaneously administered REGEN-COV 1200 mg significantly reduced progression of asymptomatic SARS-CoV-2 infection to symptomatic infection (ie, COVID-19) by 31.5% compared with placebo. REGEN-COV also reduced the overall population burden of high viral load weeks (39.7% reduction vs placebo; 48 vs 82 total weeks; P=.0010).Meaning In the current pandemic, utilization of subcutaneous REGEN-COV prevents progression of early asymptomatic infection to COVID-19 and reduces viral carriage.Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Clinical TrialNCT04452318Funding StatementSupported by Regeneron Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd. This trial was conducted jointly with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The CoVPN is supported by cooperative agreement awards from NIAID, NIH. The work on this study was supported by award numbers UM1AI068619 and UM1AI148684. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Lifespan Rhode Island Hospital IRB 2, Providence, RI (IRB# 00004624); Stanford University Research Compliance Office, Palo Alto, CA (IRB# 00004593); Geisinger Institutional Review Board GRIB, Danville, PA (IRB00008345); Advarra IRB, Columbia, MD (IRB00000971).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/. ER -